Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
Israel reports killing another senior Iranian oil official- Defeating An inability to embrace success in Scholarly world: Individual Victories
- Vote in favor of the pasta that makes good dieting pleasant!
- Merz visit highlights new strategic, and strained, Germany-Israel bond
- Nepal’s youngest premier sworn in after releasing new rap song about unity
- Pick Your #1 breakfast food
- CDC advisory panel delays vote on hepatitis B vaccines after unruly meeting
- NATO needs Ukraine's 'adaptation DNA' and an 'HOV lane' for new war tech, top commander says
- Stolen Renoir, Cézanne and Matisse were probably uninsured, market sources say
